{"id":{"repo_id":"msu","oai_identifier":"oai:d.lib.msu.edu:etd_47998"},"canonical_url":"https://search.ndltd.org/etd/msu/oai:d.lib.msu.edu:etd_47998","repository":{"repo_id":"msu","name":"Michigan State University","base_url":"https://d.lib.msu.edu/oai"},"display":{"title":"Regulation of il-6 signaling in retinal cells and tissue in health and disease","abstract":"The global prevalence of diabetic retinopathy continues to rise as more individuals are diagnosed with diabetes each year. With a rising patient population, the need for a cure is greater than ever. The current available treatment strategies are aimed at treating the more advanced stages of the disease, macular edema and neovascularization, and are not efficacious for a large portion of the patient population. In order to develop more effective and targeted therapies, a better understanding of the molecular mechanisms involved in the pathophysiology of diabetic retinopathy are needed. Chronic low-grade inflammation induced by hyperglycemia is commonly understood to play a role in disease progression. Interleukin-6 (IL-6) is a prominent inflammatory cytokine whose role in disease advancement is not well understood. The overall of effects of IL-6 are determined by two diverse signaling pathways: classical IL-6 signaling and IL-6 trans-signaling. The expression of the membrane-bound IL-6 receptor (mIL-6R) and glycoprotein 130 (gp130) are needed for classical IL-6 signaling, while gp130 and the soluble IL-6 receptor (sIL-6R) are needed for IL-6 trans-signaling. Activation of these pathways are hypothesized to promote anti-inflammatory or pro-inflammatory functions, respectively. Therefore, the aim of this study was to determine the IL-6 signaling capabilities of Human Muller and retinal endothelial cells, both of which are crucial for maintaining a healthy retina, and its effect on function and viability. In addition, this dissertation examined the regulation of IL-6 signaling pathways in response to intravitreal treatment with ranibizumab, the most common anti-VEGF therapy in patients with proliferative diabetic retinopathy and diabetic macular edema.First, we determined that human Muller cells (HMC) express both mIL-6R and gp130, which allows them to signal through both classical IL-6 and IL-6 trans-signaling. Interestingly, treatment with IL-6, the agonist of classical IL-6 signaling, protected HMCs from hyperglycemia-induced cell death. Further, these protective effects were mediated by VEGF-A. Surprisingly, treatment with IL-6/sIL-6R, the agonist of IL-6 trans-signaling, had slight protective effects, but were not dependent on VEGF-A. Second, it was established that human retinal endothelial cells (HREC) express gp130, but do not express mIL-6R. Therefore, HRECs were only responsive to IL-6 trans-signaling but not to IL-6-induced classical signaling. Treatment of HRECs with IL-6/sIL-6R (10 ng/mL) decreased cell viability and led to increased release of inflammatory cytokines. Intriguingly, when treated with a higher concentration of IL-6/sIL-6R (50 ng/mL) HRECs began releasing VEGF-A and forming tubular networks. Finally, our clinical study has shown that intravitreal ranibizumab had a strong impact on aqueous humor levels of soluble cytokine receptors, some of which belonging to IL-6 signaling. Interestingly, changes in VEGF family members (A and C) were correlated with changes in IL-6 signaling members. Taken together, all our findings suggest that an IL-6-VEGF signaling axis may be important for the development of diabetic retinopathy.","abstract_html":"The global prevalence of diabetic retinopathy continues to rise as more individuals are diagnosed with diabetes each year. With a rising patient population, the need for a cure is greater than ever. The current available treatment strategies are aimed at treating the more advanced stages of the disease, macular edema and neovascularization, and are not efficacious for a large portion of the patient population. In order to develop more effective and targeted therapies, a better understanding of the molecular mechanisms involved in the pathophysiology of diabetic retinopathy are needed. Chronic low-grade inflammation induced by hyperglycemia is commonly understood to play a role in disease progression. Interleukin-6 (IL-6) is a prominent inflammatory cytokine whose role in disease advancement is not well understood. The overall of effects of IL-6 are determined by two diverse signaling pathways: classical IL-6 signaling and IL-6 trans-signaling. The expression of the membrane-bound IL-6 receptor (mIL-6R) and glycoprotein 130 (gp130) are needed for classical IL-6 signaling, while gp130 and the soluble IL-6 receptor (sIL-6R) are needed for IL-6 trans-signaling. Activation of these pathways are hypothesized to promote anti-inflammatory or pro-inflammatory functions, respectively. Therefore, the aim of this study was to determine the IL-6 signaling capabilities of Human Muller and retinal endothelial cells, both of which are crucial for maintaining a healthy retina, and its effect on function and viability. In addition, this dissertation examined the regulation of IL-6 signaling pathways in response to intravitreal treatment with ranibizumab, the most common anti-VEGF therapy in patients with proliferative diabetic retinopathy and diabetic macular edema.First, we determined that human Muller cells (HMC) express both mIL-6R and gp130, which allows them to signal through both classical IL-6 and IL-6 trans-signaling. Interestingly, treatment with IL-6, the agonist of classical IL-6 signaling, protected HMCs from hyperglycemia-induced cell death. Further, these protective effects were mediated by VEGF-A. Surprisingly, treatment with IL-6/sIL-6R, the agonist of IL-6 trans-signaling, had slight protective effects, but were not dependent on VEGF-A. Second, it was established that human retinal endothelial cells (HREC) express gp130, but do not express mIL-6R. Therefore, HRECs were only responsive to IL-6 trans-signaling but not to IL-6-induced classical signaling. Treatment of HRECs with IL-6/sIL-6R (10 ng/mL) decreased cell viability and led to increased release of inflammatory cytokines. Intriguingly, when treated with a higher concentration of IL-6/sIL-6R (50 ng/mL) HRECs began releasing VEGF-A and forming tubular networks. Finally, our clinical study has shown that intravitreal ranibizumab had a strong impact on aqueous humor levels of soluble cytokine receptors, some of which belonging to IL-6 signaling. Interestingly, changes in VEGF family members (A and C) were correlated with changes in IL-6 signaling members. Taken together, all our findings suggest that an IL-6-VEGF signaling axis may be important for the development of diabetic retinopathy.","abstract_has_math":false,"creators":["Coughlin, Brandon A."],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Mohr, Susanne","Glazer, Louis","Robison, A.J","Olson, L. Karl","Parameswaran, Narayanan"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2019,"date_issued":"2019","date_published":"2019","updated_at":"2026-11-18T18:53:16Z","subjects":["Eye--Diseases--Prevention","Diabetic retinopathy--Treatment","Diabetic retinopathy--Prevention","Diabetes--Complications","Interleukin-6"],"languages":["English"],"rights":["In Copyright"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:47998","isbn:9781085632256","isbn:1085632253","oclc:1138555566","umi:13904472","local:Coughlin_grad.msu_0128D_16959"],"render_values":[{"text":"etd:47998","href":null,"code":true},{"text":"isbn:9781085632256","href":null,"code":true},{"text":"isbn:1085632253","href":null,"code":true},{"text":"oclc:1138555566","href":null,"code":true},{"text":"umi:13904472","href":null,"code":true},{"text":"local:Coughlin_grad.msu_0128D_16959","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://d.lib.msu.edu/oai?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Ad.lib.msu.edu%3Aetd_47998","prefix":"oai_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Mohr, Susanne","Glazer, Louis","Robison, A.J","Olson, L. Karl","Parameswaran, Narayanan"]},{"key":"dc:creator","label":"Author","values":["Coughlin, Brandon A."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2019"]},{"key":"dc:relation","label":"Dc Relation","values":["Electronic Theses & Dissertations"]},{"key":"dc:type","label":"Dc Type","values":["Text","Theses"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Eye--Diseases--Prevention","Diabetic retinopathy--Treatment","Diabetic retinopathy--Prevention","Diabetes--Complications","Interleukin-6"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["English"]},{"key":"dc:rights","label":"Dc Rights","values":["In Copyright"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:47998","isbn:9781085632256","isbn:1085632253","oclc:1138555566","umi:13904472","local:Coughlin_grad.msu_0128D_16959"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["The global prevalence of diabetic retinopathy continues to rise as more individuals are diagnosed with diabetes each year. With a rising patient population, the need for a cure is greater than ever. The current available treatment strategies are aimed at treating the more advanced stages of the disease, macular edema and neovascularization, and are not efficacious for a large portion of the patient population. In order to develop more effective and targeted therapies, a better understanding of the molecular mechanisms involved in the pathophysiology of diabetic retinopathy are needed. Chronic low-grade inflammation induced by hyperglycemia is commonly understood to play a role in disease progression. Interleukin-6 (IL-6) is a prominent inflammatory cytokine whose role in disease advancement is not well understood. The overall of effects of IL-6 are determined by two diverse signaling pathways: classical IL-6 signaling and IL-6 trans-signaling. The expression of the membrane-bound IL-6 receptor (mIL-6R) and glycoprotein 130 (gp130) are needed for classical IL-6 signaling, while gp130 and the soluble IL-6 receptor (sIL-6R) are needed for IL-6 trans-signaling. Activation of these pathways are hypothesized to promote anti-inflammatory or pro-inflammatory functions, respectively. Therefore, the aim of this study was to determine the IL-6 signaling capabilities of Human Muller and retinal endothelial cells, both of which are crucial for maintaining a healthy retina, and its effect on function and viability. In addition, this dissertation examined the regulation of IL-6 signaling pathways in response to intravitreal treatment with ranibizumab, the most common anti-VEGF therapy in patients with proliferative diabetic retinopathy and diabetic macular edema.First, we determined that human Muller cells (HMC) express both mIL-6R and gp130, which allows them to signal through both classical IL-6 and IL-6 trans-signaling. Interestingly, treatment with IL-6, the agonist of classical IL-6 signaling, protected HMCs from hyperglycemia-induced cell death. Further, these protective effects were mediated by VEGF-A. Surprisingly, treatment with IL-6/sIL-6R, the agonist of IL-6 trans-signaling, had slight protective effects, but were not dependent on VEGF-A. Second, it was established that human retinal endothelial cells (HREC) express gp130, but do not express mIL-6R. Therefore, HRECs were only responsive to IL-6 trans-signaling but not to IL-6-induced classical signaling. Treatment of HRECs with IL-6/sIL-6R (10 ng/mL) decreased cell viability and led to increased release of inflammatory cytokines. Intriguingly, when treated with a higher concentration of IL-6/sIL-6R (50 ng/mL) HRECs began releasing VEGF-A and forming tubular networks. Finally, our clinical study has shown that intravitreal ranibizumab had a strong impact on aqueous humor levels of soluble cytokine receptors, some of which belonging to IL-6 signaling. Interestingly, changes in VEGF family members (A and C) were correlated with changes in IL-6 signaling members. Taken together, all our findings suggest that an IL-6-VEGF signaling axis may be important for the development of diabetic retinopathy.","Thesis (Ph. D.)--Michigan State University. Physiology, 2019","Includes bibliographical references"]},{"key":"dc:format","label":"Dc Format","values":["xiv, 182 pages","application/pdf"]},{"key":"dc:title","label":"Title","values":["Regulation of il-6 signaling in retinal cells and tissue in health and disease"]}]}],"canonical_facts":{"dc:contributor":["Mohr, Susanne","Glazer, Louis","Robison, A.J","Olson, L. Karl","Parameswaran, Narayanan"],"dc:creator":["Coughlin, Brandon A."],"dc:date":["2019"],"dc:description":["The global prevalence of diabetic retinopathy continues to rise as more individuals are diagnosed with diabetes each year. With a rising patient population, the need for a cure is greater than ever. The current available treatment strategies are aimed at treating the more advanced stages of the disease, macular edema and neovascularization, and are not efficacious for a large portion of the patient population. In order to develop more effective and targeted therapies, a better understanding of the molecular mechanisms involved in the pathophysiology of diabetic retinopathy are needed. Chronic low-grade inflammation induced by hyperglycemia is commonly understood to play a role in disease progression. Interleukin-6 (IL-6) is a prominent inflammatory cytokine whose role in disease advancement is not well understood. The overall of effects of IL-6 are determined by two diverse signaling pathways: classical IL-6 signaling and IL-6 trans-signaling. The expression of the membrane-bound IL-6 receptor (mIL-6R) and glycoprotein 130 (gp130) are needed for classical IL-6 signaling, while gp130 and the soluble IL-6 receptor (sIL-6R) are needed for IL-6 trans-signaling. Activation of these pathways are hypothesized to promote anti-inflammatory or pro-inflammatory functions, respectively. Therefore, the aim of this study was to determine the IL-6 signaling capabilities of Human Muller and retinal endothelial cells, both of which are crucial for maintaining a healthy retina, and its effect on function and viability. In addition, this dissertation examined the regulation of IL-6 signaling pathways in response to intravitreal treatment with ranibizumab, the most common anti-VEGF therapy in patients with proliferative diabetic retinopathy and diabetic macular edema.First, we determined that human Muller cells (HMC) express both mIL-6R and gp130, which allows them to signal through both classical IL-6 and IL-6 trans-signaling. Interestingly, treatment with IL-6, the agonist of classical IL-6 signaling, protected HMCs from hyperglycemia-induced cell death. Further, these protective effects were mediated by VEGF-A. Surprisingly, treatment with IL-6/sIL-6R, the agonist of IL-6 trans-signaling, had slight protective effects, but were not dependent on VEGF-A. Second, it was established that human retinal endothelial cells (HREC) express gp130, but do not express mIL-6R. Therefore, HRECs were only responsive to IL-6 trans-signaling but not to IL-6-induced classical signaling. Treatment of HRECs with IL-6/sIL-6R (10 ng/mL) decreased cell viability and led to increased release of inflammatory cytokines. Intriguingly, when treated with a higher concentration of IL-6/sIL-6R (50 ng/mL) HRECs began releasing VEGF-A and forming tubular networks. Finally, our clinical study has shown that intravitreal ranibizumab had a strong impact on aqueous humor levels of soluble cytokine receptors, some of which belonging to IL-6 signaling. Interestingly, changes in VEGF family members (A and C) were correlated with changes in IL-6 signaling members. Taken together, all our findings suggest that an IL-6-VEGF signaling axis may be important for the development of diabetic retinopathy.","Thesis (Ph. D.)--Michigan State University. Physiology, 2019","Includes bibliographical references"],"dc:format":["xiv, 182 pages","application/pdf"],"dc:identifier":["etd:47998","isbn:9781085632256","isbn:1085632253","oclc:1138555566","umi:13904472","local:Coughlin_grad.msu_0128D_16959"],"dc:language":["English"],"dc:relation":["Electronic Theses & Dissertations"],"dc:rights":["In Copyright"],"dc:subject":["Eye--Diseases--Prevention","Diabetic retinopathy--Treatment","Diabetic retinopathy--Prevention","Diabetes--Complications","Interleukin-6"],"dc:title":["Regulation of il-6 signaling in retinal cells and tissue in health and disease"],"dc:type":["Text","Theses"]},"updated_at":"2026-11-18T18:53:16Z"}